REQUEST A DEMO
Total
USD $0.00
Search more companies

Dream Cis Inc. (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: Dream Cis Inc. Profile Updated: July 08, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company principally engaged in the business of contract clinical trial. The Company mainly provides services include regulatory post-marketing surveillance (rPMS), clinical trial, non-interventional study (NIS) and others. The Company provides its services within domestic market and to overseas markets. The Company was established on April 27, 2000. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on May 22, 2020.

Headquarters
Jeokseon Hyundai Building, 130, Sajik-Ro, Jongno-Gu
Seoul; Seoul;

Contact Details: Purchase the Dream Cis Inc. report to view the information.

Website: http://www.dreamcis.com

Basic Information
Total Employees:
Purchase the Dream Cis Inc. report to view the information.
Outstanding Shares:
Purchase the Dream Cis Inc. report to view the information.
Registered Capital:
Purchase the Dream Cis Inc. report to view the information.
Financial Auditors:
Purchase the Dream Cis Inc. report to view the information.
Incorporation Date:
April 27, 2000
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
티지디인베스트먼트
Company Performance
Financial values in the chart are available after Dream Cis Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
127.65%
Total operating revenue
128.01%
Operating profit (EBIT)
-43.51%
EBITDA
9.02%
Net Profit (Loss) for the Period
-13.62%
Total assets
88.83%
Total equity
55.23%
Operating Profit Margin (ROS)
-8.65%
Net Profit Margin
-6.5%
Return on Equity (ROE)
-0.66%
Debt to Equity Ratio
4.28%
Quick Ratio
-2.37%
Cash Ratio
0.08%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?